Evidence map›Paper›PMID 38558385›Full record

ArticleNeuropsychopharmacology reports2024

Availability of individual proteins for quantitative analysis in postmortem brains preserved in two different brain banks.

Atsuko Nagaoka, Mizuki Hino, Ryuta Izumi, Risa Shishido, Miki Ishibashi, Masataka Hatano, Makoto Sainouchi, Akiyoshi Kakita, Hiroaki Tomita, Yasuto Kunii

Open access · goldAbstract readComparative Study
In one paragraph

Article in Neuropsychopharmacology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Atsuko NagaokaDepartment of Psychiatry, Tohoku University Hospital, Sendai, Japan.ORCID https://orcid.org/0000-0002-1159-4436
Mizuki HinoDepartment of Neuropsychiatry, School of Medicine, Fukushima Medical University, Fukushima, Japan.ORCID https://orcid.org/0000-0003-3700-0322
Ryuta IzumiDepartment of Neuropsychiatry, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Risa ShishidoDepartment of Neuropsychiatry, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Miki IshibashiDepartment of Neuropsychiatry, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Masataka HatanoDepartment of Neuropsychiatry, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Makoto SainouchiDepartment of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.
Akiyoshi KakitaDepartment of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.
Hiroaki TomitaDepartment of Psychiatry, Tohoku University Hospital, Sendai, Japan.
Yasuto KuniiDepartment of Psychiatry, Tohoku University Hospital, Sendai, Japan.
Fukushima Medical University · JPNiigata University · JPTohoku University · JP

Funding

Japan Agency for Medical Research and Development JP22dm0207074Japan Agency for Medical Research and Development JP22wm0425019Japan Society for the Promotion of Science JP21H00180Japan Society for the Promotion of Science JP21K07524Japan Society for the Promotion of Science JP21K15715Niigata University 22002
6 · The paper itself

Abstract

aimPostmortem brain research is necessary for elucidating the pathology of schizophrenia; an increasing number of studies require a combination of suitable tissue samples preserved at multiple brain banks. In this study, we examined whether a comparative study of protein expression levels can be conducted using postmortem brain samples preserved in different facilities.

methodsWe compared the demographic factors of postmortem brain samples preserved in two institutions and measured and compared the expression levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and glial fibrillary acidic protein (GFAP) in the prefrontal cortex and superior temporal gyrus. GAPDH is generally used as a loading control for western blotting, and GFAP is considered as an astrocyte marker in the brain.

resultsWe found significant differences between the two institutions in postmortem interval, age at death, and preservation time. To reduce the effects of these differences on our measurements, the parameters were set as covariates in our analyses of covariance. Subsequently, no differences in GAPDH and GFAP expression were found between institutions.

conclusionsWhen studies are conducted using brain samples preserved in different brain banks, differences in demographic factors should be carefully considered and taken into account by statistical methods to minimize their impact as much as possible. Since there was no significant difference in the protein expression levels of GAPDH and GFAP in either region between the two institutions that preserved the postmortem brains, we concluded that it is possible to perform protein quantitative analysis assuming that there is no effect of difference between two institutions.

Indexed as

Glial Fibrillary Acidic ProteinTissue BanksAdultAgedBrainFemaleGlyceraldehyde-3-Phosphate DehydrogenasesHumansMaleMiddle AgedPrefrontal CortexTemporal LobeGFAP protein, humanGlial Fibrillary Acidic ProteinGlyceraldehyde-3-Phosphate Dehydrogenasesbrain bankglial fibrillary acidic proteinglyceraldehyde‐3‐phosphate dehydrogenasepostmortem brainschizophrenia

Identifiers

PMID38558385
PMCPMC11144605
OpenAlexW4393378599

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.